Chronic Myeloid Leukemia and the Application of Rational Drug Design
Dados Bibliográficos
| ID | 15744649 |
|---|---|
| Autores | Ruth M Stone (0000-0002-7526-2633, Harvard University, autor correspondente) |
| Ano | 2004 |
| Volume | 6 |
| Fascículo | 11 |
| Data de publicação | 2004-11-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | The AMA Journal of Ethic (JOURNAL) |
| Identificadores do periódico | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Editora | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/virtualmentor.2004.6.11.cprl1-0411 |
| PMID | 23260209 |
| OpenAlex | W131287579 |
| Idioma | EN |
Chronic Myeloid Leukemia (CML) is a rare disease (annual incidence in the United States of 2 in 100 000), but the understanding of its pathophysiology directly led to the development of one of the first truly specific anti-neoplastic therapies.1
Disease · Drug · Drug development · Incidence (geometry · Myeloid · Myeloid leukemia · Chronic Lymphocytic Leukemia Research · Chronic Myeloid Leukemia Treatments · HER2/EGFR in Cancer Research · Medicine · Cancer Research · Internal Medicine · Oncology · Pharmacology
| Velocidade de citação | historical |
|---|---|
| Altamente citado | Não |